Evommune, Inc. (EVMN) News
Track canonical SquawkNews coverage tagged to EVMN, Evommune, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 14 indexed stories across 8 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Evommune to Present Positive Phase 2a EVO301 Atopic Dermatitis Data as Late-Breaker at EADV 2026
Evommune announced a late-breaking oral presentation of positive Phase 2a data for EVO301 in moderate-to-severe atopic dermatitis at EADV 2026.Key Highlights:Original SEC Filing: Evommune, Inc. [ EVMN ] - 8-K - Sep. 23,
REGULATION | Sep 23, 2026, 08:15 PM UTC
L
Evommune posts updated corporate presentation outlining pipeline progress, cash runway and 2027—2028 milestones
Evommune posted an updated corporate presentation highlighting pipeline advances, ~$287M cash and runway into 2029.Key Highlights:Original SEC Filing: Evommune, Inc. [ EVMN ] - 8-K - Sep. 15, 2026This is an AI-powered su
REGULATION | Sep 15, 2026, 12:33 PM UTC
L
Evommune price target cut to $22 from $28
Leerink Partners cut its Evommune price target to $22.00 a share from $28.00, while maintaining an Outperform rating.
EQUITY | Sep 09, 2026, 04:03 PM UTC
L
RBC Capital cuts Evommune price target to $21 from $29
Benzinga, citing TradingView News, reports RBC Capital cut its Evommune price target to $21.00 per share from $29.00.
EQUITY | Sep 09, 2026, 01:43 PM UTC
M
Evommune shares plunge after eczema drug EVO756 fails mid-stage goals
Evommune (EVMN) shares fell more than 15% in extended trading after it said lead candidate EVO756 failed to meet main goals in a mid-stage eczema trial, citing topline data.
EQUITY | Sep 09, 2026, 10:51 AM UTC
M
Evommune says EVO756 phase 2b failed in atopic dermatitis
Evommune said EVO756 in moderate-to-severe atopic dermatitis did not meet primary or secondary endpoints and will be discontinued for AD.
REGULATION | Sep 09, 2026, 10:04 AM UTC
M
Evommune shares tumble 13% after-hours after eczema pill trial fails
Evommune (EVMN) shares fell 13% after-hours Tuesday after the company said its experimental eczema pill failed a mid-stage study and will not move forward in that disease.
EQUITY | Sep 08, 2026, 11:52 PM UTC
M
Evommune scraps eczema drug after mid-stage trial misses main goal
Evommune said it will not advance its experimental skin disease drug after failing to meet the main goal in a mid-stage trial, sending shares down 24% in aftermarket trading.
EQUITY | Sep 08, 2026, 10:17 PM UTC
L
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results
EQUITY | Sep 08, 2026, 10:10 PM UTC
H
EVMN Initiates Migraine Trial
EVMN starts phase 2b trial
EQUITY | Jul 30, 2026, 12:02 PM UTC
H
Top 3 Health Care Stocks That May Rocket Higher In July
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength o
EARNINGS | Jul 06, 2026, 10:11 AM UTC
L
Morgan Stanley Maintains Overweight on Evommune, Lowers Price Target to $26
Morgan Stanley analyst Judah Frommer maintains Evommune (NYSE: EVMN ) with a Overweight and lowers the price target from $55 to $26.
EQUITY | Jun 30, 2026, 12:56 PM UTC
L
This AAR Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Baird analyst RJ
EQUITY | Jun 30, 2026, 12:51 PM UTC
H
Crude Oil Gains 2%; Comcast Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 points on Monday. The Dow traded up 0.44% to 52,105.66 while the NASDAQ rose 1.33% to 25,634.54. The S&P 500 also rose, gai
CENTRAL_BANK | Jun 29, 2026, 04:30 PM UTC